Minerva Neurosciences (NERV) Projected to Post Quarterly Earnings on Thursday

Minerva Neurosciences (NASDAQ:NERV) will likely be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Minerva Neurosciences to post earnings of ($1.05) per share for the quarter.

Minerva Neurosciences Price Performance

Shares of NERV opened at $1.79 on Tuesday. The firm has a market cap of $12.52 million, a PE ratio of -4.07 and a beta of 0.12. The stock’s fifty day moving average price is $2.18 and its two-hundred day moving average price is $2.41. Minerva Neurosciences has a 1 year low of $1.77 and a 1 year high of $7.53.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, November 6th. StockNews.com assumed coverage on Minerva Neurosciences in a research note on Saturday. They issued a “sell” rating on the stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.